Literature DB >> 22057658

Profiling of serum antibodies with printed glycan array: room for data misinterpretation.

Polina Obukhova1, Vladimir Piskarev, Vyacheslav Severov, Galina Pazynina, Alexander Tuzikov, Maxim Navakouski, Nadezhda Shilova, Nicolai Bovin.   

Abstract

Using an example of Galβ1-3GlcNAc (Le(C)) related glycans, we here demonstrate a risk of data misinterpretation when polyclonal antibodies are probed for their glycan-binding specificities with help of a printed glycan array (PGA). Affinity isolation of antibodies from human serum using Le(C)-Sepharose or 3'-O-SuLe(C)-Sepharose in conditions of excess of the adsorbents generated identical material regardless of the affinity ligand, with the antibodies equally capable of binding to Le(C) and to 3'-O-SuLe(C) disaccharides, as well as to 3'-O-SiaLe(C) trisaccharide. More detailed profiling has shown that the isolated antibodies bind to the inner part of Galβ1-3GlcNAc disaccharide. We therefore conclude that serum does not contain different subsets of antibodies specific either to Le(C) or to 3'-O-SuLe(C), despite their visibly different binding signals to these glycans on PGA. © Springer Science+Business Media, LLC 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057658     DOI: 10.1007/s10719-011-9355-0

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  6 in total

1.  Design of the blood group AB glycotope.

Authors:  E Y Korchagina; T V Pochechueva; P S Obukhova; A A Formanovsky; A Imberty; R Rieben; N V Bovin
Journal:  Glycoconj J       Date:  2005-03       Impact factor: 2.916

2.  Printed covalent glycan array for ligand profiling of diverse glycan binding proteins.

Authors:  Ola Blixt; Steve Head; Tony Mondala; Christopher Scanlan; Margaret E Huflejt; Richard Alvarez; Marian C Bryan; Fabio Fazio; Daniel Calarese; James Stevens; Nahid Razi; David J Stevens; John J Skehel; Irma van Die; Dennis R Burton; Ian A Wilson; Richard Cummings; Nicolai Bovin; Chi-Huey Wong; James C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

3.  Normal human serum contains high levels of anti-Gal alpha 1-4GlcNAc antibodies.

Authors:  Polina Obukhova; Robert Rieben; Nicolai Bovin
Journal:  Xenotransplantation       Date:  2007-11       Impact factor: 3.907

4.  Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges.

Authors:  Margaret E Huflejt; Marko Vuskovic; Daniela Vasiliu; Hongyu Xu; Polina Obukhova; Nadezhda Shilova; Alexander Tuzikov; Oxana Galanina; Banu Arun; Karen Lu; Nicolai Bovin
Journal:  Mol Immunol       Date:  2009-07-15       Impact factor: 4.407

5.  Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass.

Authors:  Stephan von Gunten; David F Smith; Richard D Cummings; Stefan Riedel; Sylvia Miescher; Alexander Schaub; Robert G Hamilton; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2009-05-13       Impact factor: 10.793

6.  Synthesis of polymeric neoglycoconjugates based on N-substituted polyacrylamides.

Authors:  N V Bovin; T V Zemlyanukhina; N E Byramova; O E Galanina; A E Zemlyakov; A E Ivanov; V P Zubov; L V Mochalova
Journal:  Glycoconj J       Date:  1993-04       Impact factor: 2.916

  6 in total
  3 in total

1.  The Glycan Array Platform as a Tool to Identify Carbohydrate Antigens.

Authors:  Li Xia; Jeffrey C Gildersleeve
Journal:  Methods Mol Biol       Date:  2015

Review 2.  Carbohydrate microarrays.

Authors:  Sungjin Park; Jeffrey C Gildersleeve; Ola Blixt; Injae Shin
Journal:  Chem Soc Rev       Date:  2012-11-28       Impact factor: 54.564

3.  Human Natural Antibodies Recognizing Glycan Galβ1-3GlcNAc (LeC).

Authors:  Kira Dobrochaeva; Nailya Khasbiullina; Nadezhda Shilova; Nadezhda Antipova; Polina Obukhova; Oxana Galanina; Mikhail Gorbach; Inna Popova; Sergey Khaidukov; Natalia Grishchenko; Nikolai Tupitsyn; Jacques Le Pendu; Nicolai Bovin
Journal:  Int J Mol Sci       Date:  2020-09-05       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.